Past Event
1 August 2011 - 5 August 2011,
University of Siena, Italy
Co‑chaired by Emanuele Montomoli (Univ. of Siena, Italy) and Lars Haaheim (Univ. of Bergen, Norway).
35 attendees from Australia, Europe, Egypt, India, Senegal, South America, USA.
Five-day intensive course in 8 thematic modules; Societal impact of influenza; Global surveillance & prevention; Human & animal influenza; Pathogenesis; Immunology; Vaccines; Antivirals and Regulatory issues.
Faculty Highlights: Over 20 expert lecturers from top institutions
Social & Networking: Evening receptions and Tuscany visits offered immersive networking and cultural experiences.
Participants praised Siena’s beauty and the school as ideal for informal interactions.
Lars Haaheim passed away just months before the event; his contributions were honoured through tributes and the Lars Haaheim Travel Fellowship in his memory.
| Session/Theme | Title | Speaker (Affiliation) |
| Day 1: 1 August 2011 | ||
| Introduction | Welcome and Opening Remarks | Emanuele Montomoli (University of Siena, Italy): Jackie Katz (CDC, Atlanta, USA): |
| Theme 1: Societal Impact | History and societal impact | Christopher W. Potter (University of Sheffield Medical School, UK – retired) |
| Global influenza epidemiology and surveillance | Lyn Finelli (CDC, Atlanta, USA) | |
| Theme 2: Global Surveillance and Prevention | Influenza epidemiology | Roberto Gasparini (University of Genova, Italy) |
| Vaccination policy | Geert Leroux-Roels (University of Ghent, Belgium) | |
| Virological surveillance and genotyping | Olav Hungnes (Norwegian Institute of Public Health, Oslo, Norway) | |
| Day 2: 2 August 2011 | ||
| Theme 3: Human and Animal Influenza | Viral structure and replication | Sylvie Van der Werf (Institut Pasteur, Paris, France) |
| Animal influenza | Giovanni Cattoli (IZSVe, Padova, Italy) | |
| Theme 4: Pathogenesis | Human influenza | Karl G. Nicholson (University of Leicester, UK) |
| Spanish flu | Alan Hay (NIMR, London, UK) | |
| Molecular determinants of pathogenicity | Hans Dieter Klenk (University of Marburg, Germany) | |
| Day 3: 3 August 2011 | ||
| Theme 5: Immunology | Basic immunology | Jackie Katz (CDC, Atlanta, USA) |
| Adjuvants | Rino Rappuoli (Novartis Vaccines, Siena, Italy) | |
| Theme 6: Vaccines | Epidemiology of seasonal and pandemic vaccination | David S. Fedson (Sergy Haut, France) |
| Inactivated vaccines | Otfried Kistner (Baxter Innovation GmbH) | |
| Day 4: 4 August 2011 | ||
| Theme 6: Vaccines | Live attenuated vaccines | John Treanor (University of Rochester Medical Center, USA) |
| New platforms for vaccine production | Alan Shaw (VaxInnate Corporation, Cranbury, USA) | |
| Theme 7: Antivirals | Anti-influenza (M2 and NA) drugs | Alan Hay (NIMR, London, UK) |
| New and old drugs | David S. Fedson (Sergy Haut, France) | |
| Remarks on Pandemic 2009 | Severity and lessons learned | Angus Nicoll (ECDC, Stockholm, Sweden) |
| Day 5: 5 August 2011 | ||
| Theme 8: Regulatory Issues | Licensing requirements – a personal perspective | John Wood (NIBSC, UK – retired) |
| Correlates of protection | Rebecca J. Cox (University of Bergen, Norway) | |
| Regulatory challenges | Bettie CG Voordouw (Medicines Evaluation Board, Netherlands) | |
| Closing Remarks | Summary and farewell | |
